Raghuveer K. Ramachandra, Ph.D.
Affiliations: | 2007 | West Virginia University, Morgantown, WV, United States |
Area:
Animal Physiology BiologyGoogle:
"Raghuveer Ramachandra"Parents
Sign in to add mentor| Jianbo Yao | grad student | 2007 | West Virginia University | |
| (Expression profiling of oocyte specific genes, transcription factors and microRNAs during early embryonic development in rainbow trout (Onchorhyncus mykiss).) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sasikumar PG, Ramachandra RK, Adurthi S, et al. (2019) A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy. Molecular Cancer Therapeutics |
| Sasikumar PG, Naremaddepalli SS, Ramachandra RK, et al. (2019) Abstract 4148: An orally bioavailable small molecule antagonist of TIM-3 signaling pathway shows potent anti-tumor activity Cancer Research. 79: 4148-4148 |
| Holmström TH, Moilanen AM, Ikonen T, et al. (2018) ODM-203 a selective inhibitor of FGFR and VEGFR, shows strong anti-tumor activity, and induces anti-tumor immunity. Molecular Cancer Therapeutics |
| Sasikumar PG, Naremaddepalli SS, Ramachandra RK, et al. (2018) Abstract B006: Functional antagonism of VSIG8-mediated immune suppression by oral VISTA agents Molecular Cancer Therapeutics. 17 |
| Lazorchak AS, Patterson T, Ding Y, et al. (2017) Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer Cancer Immunology Research. 5 |
| Murone M, Vaslin Chessex A, Attinger A, et al. (2016) Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. Molecular Cancer Therapeutics |
| Chikanna D, Lakshminarasimhan A, Khairnar V, et al. (2016) Abstract A72: Novel NAMPT inhibitors for the treatment of Pancreatic cancer Molecular Cancer Research. 14 |
| Sasikumar P, Sudarshan NS, Gowda N, et al. (2016) Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy Cancer Research. 76: 4861-4861 |
| Satyam LK, Poddutoori R, Mukherjee S, et al. (2016) Abstract 3070: Potent and selective inhibition of CDK7 by novel covalent inhibitors Cancer Research. 76: 3070-3070 |
| Chikkanna D, Lakshminarasimhan A, Khairnar V, et al. (2015) Abstract 5367: Discovery of dihydro-isoxazole derivatives as novel inhibitors of NAMPT for the treatment of multiple myeloma Cancer Research. 75: 5367-5367 |